CSIMarket
 


Lucira Health Inc   (LHDX)
Other Ticker:  
 
 

LHDX's Operating Income Growth by Quarter and Year

Lucira Health Inc 's Operating Income results by quarter and year




LHDX Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -8.01 0.00 0.00
III Quarter September -126.29 -27.61 0.00 0.00
II Quarter June -21.39 -16.28 0.00 0.00
I Quarter March 13.81 -13.23 0.00 0.00
FY   -133.87 -65.13 0.00 0.00



LHDX Operating Income third quarter 2022 Y/Y Growth Comment
Lucira Health Inc in the third quarter 2022 recorded Operating Loss of $ -126.29 millions.

According to the results reported in the third quarter 2022, Lucira Health Inc achieved the best Operating Income growth in In Vitro & In Vivo Diagnostic Substances industry. While Lucira Health Inc ' s Operating Income no change of % ranks overall at the positon no. in the third quarter 2022.

Explain Operating Income growth


LHDX Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Lucira Health Inc 's third quarter 2022 Operating Income $ -126.29 millions LHDX's Income Statement
Lucira Health Inc 's third quarter 2021 Operating Income $ -27.61 millions Quarterly LHDX's Income Statement
New: More LHDX's historic Operating Income Growth >>


LHDX Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income third quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Lucira Health Inc 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LHDX's III. Quarter Q/Q Operating Income Comment
III. Quarter 2022 results of -126.29 millions by Lucira Health Inc look even worse considering the -21.39 millions in the previous quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Lucira Health Inc achieved highest sequential Operating Income growth. While Lucira Health Inc 's Operating Income growth quarter on quarter, overall rank is .


Operating Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


LHDX's III. Quarter Q/Q Operating Income Comment
Recent results of -126.29 millions by Lucira Health Inc come out even less good compare to the Operating Loss -21.39 millions in the second quarter.

Within In Vitro & In Vivo Diagnostic Substances industry Lucira Health Inc achieved highest sequential Operating Income growth. While Lucira Health Inc 's Operating Income growth quarter on quarter, overall rank is .


Lucira Health Inc 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Sep 30 2022)
12 Months Ending
(Jun 30 2022)
12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
Cumulative Operating Income 12 Months Ending $ -141.88 $ -43.20 $ -38.09 $ -65.14 $ 0.00
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Lucira Health Inc ' has realized cumulative trailing twelve months Operating Loss of $ -142 millions in the Sep 30 2022 period.
The business is detiriorating as the cumulative Operating Loss is becoming larger from $ -43.2 millions for the period from Jun 30 2022 to Sep 30 2021 and $ millions from the TTM period ending Sep 30 2021 Dhruv Khan  mentioned.

Lucira Health Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Lucira Health Inc ' has realized cumulative trailing twelve months Operating Loss of $ -142 millions in the Sep 30 2022 period.
The situation is getting worse as the cumulative Operating Loss is getting bigger from $ -43.2 millions in TTM ending quarter Jun 30 2022 and $ millions for the twelve months ending in the quarter a year ago Dhruv Khan  mentioned.

Lucira Health Inc achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
In Vitro & In Vivo Diagnostic Substances Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
LHDX's Operating Income Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for LHDX's Competitors
Operating Income Growth for Lucira Health Inc 's Suppliers
Operating Income Growth for LHDX's Customers

You may also want to know
LHDX's Annual Growth Rates LHDX's Profitability Ratios LHDX's Asset Turnover Ratio LHDX's Dividend Growth
LHDX's Roe LHDX's Valuation Ratios LHDX's Financial Strength Ratios LHDX's Dividend Payout Ratio
LHDX's Roa LHDX's Inventory Turnover Ratio LHDX's Growth Rates LHDX's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Sep 30 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Sep 30 2022
Harvard Bioscience Inc586.50%$ 586.496 millions
Avanos Medical Inc 419.44%$ 419.444 millions
Ufp Technologies Inc 411.42%$ 411.424 millions
The Pennant Group Inc 319.74%$ 319.741 millions
Dynavax Technologies Corporation282.11%$ 282.107 millions
Vaso Corporation281.76%$ 281.761 millions
Innoviva Inc 202.92%$ 202.924 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com